- Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
This study looks at new ways to treat childhood leukaemia (ALL) in children and teenagers. It aims to make treatments kinder and more effective by using smart medicines (immunotherapy) and targeting specific cancer features, reducing the need for harsh chemotherapy.
For: Acute Lymphoblastic Leukemia, PediatricAustralia · Austria · Czechia - Active not recruitingPHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
This study looks at a new cell therapy called JNJ-68284528 for people with multiple myeloma. It aims to see how well it works in clearing up any remaining cancer cells after treatment.
For: Multiple MyelomaUnited States · Belgium · France - Active not recruitingPHASE3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous therapy. It aims to see if a new combination, IberDd, works better and is safer than a standard combination, DVd, for patients in the UK.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
For: Newly Diagnosed Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
This study is testing a new medicine called elranatamab for people with a type of blood cancer called multiple myeloma. It's for those whose cancer has returned after other treatments. We want to see if elranatamab works better than standard medicines.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
For: Multiple MyelomaGermany - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
For: Multiple MyelomaUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
For: Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
For: Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
For: Multiple MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
This study looks at new drug combinations for a serious condition called AL amyloidosis, which affects the heart. We want to see how safe these treatments are for the heart and how they work in different people, especially those from diverse backgrounds.
For: AmyloidosisUnited States · Canada · China - Active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
For: Multiple MyelomaUnited States · Belgium · Canada - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
For: Relapsed or Refractory Multiple MyelomaUnited States · Argentina · Australia - RecruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study looks at a new combination treatment for newly diagnosed multiple myeloma. It combines an existing drug, belantamab mafodotin, with standard treatments (VRd) to see if it's safe and effective, and to find the best dose.
For: Multiple MyelomaUnited States · Australia · Canada - RecruitingPHASE3
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
This study compares two treatments for newly diagnosed multiple myeloma in adults who can't have a stem cell transplant. It aims to see if a combination including Elranatamab is better than another standard combination at controlling the cancer and improving patients' lives.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
This study looks at new drug combinations for babies with a type of blood cancer called acute lymphoblastic leukaemia (ALL). It explores how well new drugs, bortezomib and vorinostat, work with standard treatments and checks for any side effects, aiming to improve treatment outcomes for these infants.
For: Acute Lymphoblastic LeukemiaUnited States · Canada - Active not recruitingPHASE3
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
This study is looking at a new treatment called isatuximab, combined with other treatments, for adults newly diagnosed with a type of blood cancer called multiple myeloma. It's for those who aren't able to have a stem cell transplant and aims to see if the new combination can help people live longer without their cancer getting worse.
For: Plasma Cell MyelomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
This study looks at adding a new drug, Isatuximab, to standard treatment for newly diagnosed multiple myeloma. It aims to see if Isatuximab improves outcomes both during initial treatment and during ongoing maintenance therapy.
For: Multiple MyelomaGermany - Active not recruitingPHASE2
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This study looks at new treatments for younger adults with newly diagnosed multiple myeloma. It tests combinations of medications like teclistamab and talquetamab, depending on whether a small amount of cancer is still present after initial treatment. The goal is to find better ways to manage the disease.
For: Multiple MyelomaFrance - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
This study looks at a new way to give belantamab mafodotin, along with other common medicines, for multiple myeloma that has come back or isn't responding well. We want to see if giving it less often can still work well and cause fewer eye side effects.
For: Multiple MyelomaUnited States · France · Germany - Active not recruitingPHASE3
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
This study compares a new cell therapy (Cilta-cel) with standard treatments for multiple myeloma, a type of blood cancer. It's for people whose cancer has returned or isn't responding to their current medicine, especially lenalidomide, to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study looks at a new drug, linvoseltamab, for multiple myeloma that has come back or isn't responding to treatment. It compares linvoseltamab alone or with another drug, carfilzomib, against standard treatments to see if it's safer and works better.
For: Relapsed and/or Refractory Multiple Myeloma (RRMM)United States · Australia · South Korea - Active not recruitingPHASE3
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study compares two drug combinations for people with multiple myeloma that has come back or not responded well to previous treatments. It aims to see if a new combination with belantamab mafodotin is better or safer than a standard treatment.
For: Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE2
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
This study looks at new ways to treat children and teenagers with a type of blood cancer called acute lymphoblastic leukemia (ALL) that has come back. It investigates a new drug called Bortezomib to see if it can help improve treatment success for those with high-risk relapsed ALL.
For: Acute Lymphoblastic Leukemia (ALL)Australia · Austria · Belgium - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
This study looks at new treatments for multiple myeloma, a type of blood cancer. It compares a standard treatment plus a new cell therapy called cilta-cel, against the standard treatment alone, for people newly diagnosed who aren't having a stem cell transplant initially.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This study is testing a new drug called CC-220, sometimes on its own and sometimes with other standard cancer medicines, for people with multiple myeloma. It aims to find the right dose, see how safe it is, and if it helps treat the disease.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE3
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new treatment, teclistamab, with existing therapies for multiple myeloma that has come back or not responded to previous treatments. It aims to see how well teclistamab works and if it's safe for people with this condition.
For: Relapsed or Refractory Multiple MyelomaUnited States · Australia · Austria